<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902509</url>
  </required_header>
  <id_info>
    <org_study_id>RP-F647-201901</org_study_id>
    <nct_id>NCT03902509</nct_id>
  </id_info>
  <brief_title>A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.</brief_title>
  <official_title>A Randomized, Controlled, Multi-site Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using Pirfenidone to treat Grade 2 or Grade3 radiation-induced lung injury, and observe the
      efficacy and safety of the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, controlled, multi-site clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLco% change</measure>
    <time_frame>Week 8 and 24</time_frame>
    <description>Compare DLco% from basement to the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The grade change of radiation-induced lung injury</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score change of CT</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of effective lung volume</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The grade change of Cough, Dyspnea and Fever</measure>
    <time_frame>Week 8 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Radiation-induced Lung Injury</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pirfenidone + basic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controll</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>with basic treatment and without pirfenidone treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>pirfenidone capsule made in China</description>
    <arm_group_label>Pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basic treatment</intervention_name>
    <description>glucocorticoid and expectant treatment etc.</description>
    <arm_group_label>Controll</arm_group_label>
    <arm_group_label>Pirfenidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-75 years old (including 18 and 75 years);

          2. clinically diagnosed grade 2 or 3 radiation-induced lung injury;

          3. the course of radiation-induced lung injury is less than 2 months;

          4. ECOG 0-2;

          5. the expected survival time is more than 6 months;

          6. the functional level of major organs meets the following standards:
             ANC≥3.0×109/L，PLT≥100×109/L，Hb≥90g/L, TBIL、BUN and Cr≤1.5×ULN， ALT、AST≤2.0×ULN

          7. capable of eating solid food upon enrollment;

          8. subjects will voluntarily participate in this study and sign the informed consent.

        Exclusion Criteria:

          1. have a history of chronic bronchial acute attack or severe pulmonary heart disease;

          2. pneumonectomy;

          3. tumor progression;

          4. severe pulmonary infection;

          5. creatinine clearance rate &lt; 30ml/min, severe renal disease or need dialysis;

          6. concomitant with other serious diseases: for example, myocardial infarction within 6
             months, uncontrolled diabetes, etc., were considered not suitable for the participants
             in the study;

          7. patients with active peptic ulcer;

          8. pregnant women and patients with mental illness;

          9. participating in clinical trials of other drugs within 3 months;

         10. the investigator determined that subject was not suitable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lvhua Wang</last_name>
    <phone>+86 10-67781331</phone>
    <email>cancergcp@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Chen</last_name>
    <phone>+86 0571-88122222</phone>
    <email>zjzliec@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lvhua Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pirfenidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

